Heier Jeffrey S.

SEC source: 0001104659-26-114080 · tm2627084-1_4seq1.xml · nonDerivative · entry 1

Heier Jeffrey S. · CIK 0001653082 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 307,457

F1 · kind: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on October 1, 2026. The sales do not represent a discretionary trade by the reporting person.

F1 · shares: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on October 1, 2026. The sales do not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.9900 to $7.2100, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-26-101670 · tm2624096-2_4seq1.xml · nonDerivative · entry 1

Heier Jeffrey S. · CIK 0001653082 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 318,326

F1 · kind: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on August 22, 2026. The sales do not represent a discretionary trade by the reporting person.

F1 · shares: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on August 22, 2026. The sales do not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.6425 to $10.9125, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

F3 · balance_after: Includes 1,272 shares of common stock acquired under the Corporation's Amended and Restated 2014 Employee Stock Purchase Plan on June 30, 2026.

SEC source: 0001104659-26-067481 · tm2615856-2_4seq1.xml · nonDerivative · entry 1

Heier Jeffrey S. · CIK 0001653082 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 320,350

F1 · kind: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on May 22, 2026. The sales do not represent a discretionary trade by the reporting person.

F1 · shares: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on May 22, 2026. The sales do not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.1529 to $8.2509, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-26-019803 · tm267255-2_4seq1.xml · nonDerivative · entry 1

Heier Jeffrey S. · CIK 0001653082 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 323,368

F1 · kind: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on February 22, 2026. The sales do not represent a discretionary trade by the reporting person.

F1 · shares: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on February 22, 2026. The sales do not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.2150 to $8.3500, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-26-001284 · tm261962-2_4seq1.xml · derivative · entry 2

Heier Jeffrey S. · CIK 0001653082 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 240,932

Underlying: Common Stock · 240,932 shares

Expires 2036-01-01

F3 · derivative.exercise_date: Subject to the reporting person's continued service to the Corporation, the shares underlying this option vest over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant.

SEC source: 0001104659-26-001284 · tm261962-2_4seq1.xml · nonDerivative · entry 1

Heier Jeffrey S. · CIK 0001653082 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 326,425

F1 · shares: On January 2, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Corporation"). Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter.

F2 · balance_after: Includes 1,373 shares of common stock acquired under the Corporation's Amended and Restated 2014 Employee Stock Purchase Plan on December 31, 2025.

SEC source: 0001104659-25-116420 · tm2532258-1_4seq1.xml · nonDerivative · entry 1

Heier Jeffrey S. · CIK 0001653082 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 245,940

F1 · kind: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on November 22, 2025. The sales do not represent a discretionary trade by the reporting person.

F1 · shares: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on November 22, 2025. The sales do not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.80 to $12.3207, inclusive. The reporting person undertakes to provide to the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-25-097163 · tm2528026-1_4seq1.xml · nonDerivative · entry 1

Heier Jeffrey S. · CIK 0001653082 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 249,409

F1 · kind: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on October 1, 2025. The sales do not represent a discretionary trade by the reporting person.

F1 · shares: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on October 1, 2025. The sales do not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.99 to $11.0866, inclusive. The reporting person undertakes to provide to the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-25-084115 · tm2524438-2_4seq1.xml · nonDerivative · entry 1

Heier Jeffrey S. · CIK 0001653082 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 259,911

F1 · kind: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on August 22, 2025. The sales do not represent a discretionary trade by the reporting person.

F1 · shares: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on August 22, 2025. The sales do not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.89 to $12.16, inclusive. The reporting person undertakes to provide to the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-25-053090 · tm2516174-2_4seq1.xml · nonDerivative · entry 1

Heier Jeffrey S. · CIK 0001653082 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 262,974

F1 · kind: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on May 22, 2025. The sales do not represent a discretionary trade by the reporting person.

F1 · shares: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on May 22, 2025. The sales do not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.06 to $7.29, inclusive. The reporting person undertakes to provide to the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-25-017567 · tm257640-3_4seq1.xml · nonDerivative · entry 1

Heier Jeffrey S. · CIK 0001653082 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 265,998

F1 · kind: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on February 22, 2025. The sales do not represent a discretionary trade by the reporting person.

F1 · shares: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on February 22, 2025. The sales do not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.78 to $6.99, inclusive. The reporting person undertakes to provide to the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-24-123417 · tm2429613-2_4seq1.xml · nonDerivative · entry 1

Heier Jeffrey S. · CIK 0001653082 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 269,059

F1 · kind: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on November 22, 2024. The sales do not represent a discretionary trade by the reporting person.

F1 · shares: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on November 22, 2024. The sales do not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.87 to $9.10, inclusive. The reporting person undertakes to provide to the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-24-106327 · tm2425639-3_4seq1.xml · derivative · entry 2

Heier Jeffrey S. · CIK 0001653082 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2034-10-01

F2 · derivative.exercise_date: Vests over four years, with 1/48 of the shares vesting monthly beginning on November 1, 2024.

SEC source: 0001104659-24-106327 · tm2425639-3_4seq1.xml · nonDerivative · entry 1

Heier Jeffrey S. · CIK 0001653082 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 272,007

F1 · shares: On October 2, 2024, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Corporation"). Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, in equal annual installments, beginning on October 1, 2025.

SEC source: 0001104659-23-093601 · tm2324202-1_4seq1.xml · derivative · entry 1

Heier Jeffrey S. · CIK 0001653082 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,350

Underlying: Common Stock · 17,350 shares

Expires 2033-08-01

F1 · derivative.exercise_date: Subject to the reporting person's continued service as a consultant to the Company, the option will vest over one year, with 1/12 of the shares underlying the option vesting monthly beginning on the one-month anniversary of the Vesting Commencement Date. The Vesting Commencement Date for this award is July 1, 2023.

SEC source: 0001104659-23-072400 · tm2318782-2_4seq1.xml · derivative · entry 2

Heier Jeffrey S. · CIK 0001653082 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,000

Underlying: Common Stock · 36,000 shares

Expires 2033-06-13

F2 · derivative.exercise_date: Subject to the reporting person's continued service on the Company's board of directors, the options will vest with respect to 100% of the shares underlying the options on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date.

SEC source: 0001104659-23-072400 · tm2318782-2_4seq1.xml · nonDerivative · entry 1

Heier Jeffrey S. · CIK 0001653082 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,933

F1 · shares: On June 14, 2023, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date.

SEC source: 0001104659-22-109735 · tm2228420-1_4seq1.xml · derivative · entry 1

Heier Jeffrey S. · CIK 0001653082 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2032-10-16

F1 · derivative.exercise_date: Vests over four years, with 1/48 of the shares underlying the option vesting monthly beginning on August 1, 2022.

SEC source: 0001104659-22-073146 · tm2218958-1_4seq1.xml · derivative · entry 2

Heier Jeffrey S. · CIK 0001653082 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,800

Underlying: Common Stock · 26,800 shares

Expires 2032-06-15

F2 · derivative.exercise_date: Subject to the reporting person's continued service on the Company's board of directors, the options will vest with respect to 100% of the shares underlying the options on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date.

SEC source: 0001104659-22-073146 · tm2218958-1_4seq1.xml · nonDerivative · entry 1

Heier Jeffrey S. · CIK 0001653082 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,933

F1 · shares: On June 16, 2022, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date.

SEC source: 0001104659-22-061314 · tm2215653-1_4seq1.xml · nonDerivative · entry 1

Heier Jeffrey S. · CIK 0001653082 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,000

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.015 to $3.05, inclusive. The reporting person undertakes to provide to Ocular Therapeutix, Inc., any security holder of Ocular Therapeutix, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-21-084294 · tm2120338-1_4seq1.xml · derivative · entry 1

Heier Jeffrey S. · CIK 0001653082 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2031-06-17

F1 · derivative.exercise_date: Vests with respect to 100% of the securities on the first anniversary of the grant date.

SEC source: 0001104659-20-077441 · a4.xml · derivative · entry 1

Heier Jeffrey S. · CIK 0001653082 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2030-06-24

F1 · derivative.exercise_date: Vests with respect to 100% of the securities on the first anniversary of the grant date.

SEC source: 0001104659-19-035411 · a4.xml · derivative · entry 1

Heier Jeffrey S. · CIK 0001653082 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2029-06-10

F1 · derivative.exercise_date: Vests with respect to 100% of the securities on the first anniversary of the grant date.

SEC source: 0001104659-19-015692 · a4.xml · nonDerivative · entry 1

Heier Jeffrey S. · CIK 0001653082 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,000

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.15 to $4.16, inclusive. The reporting person undertakes to provide to Ocular Therapeutix, Inc., any security holder of Ocular Therapeutix, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

SEC source: 0001104659-18-040497 · a4.xml · derivative · entry 1

Heier Jeffrey S. · CIK 0001653082 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2028-06-13

F1 · derivative.exercise_date: Vests with respect to 100% of the securities on the first anniversary of the grant date.

SEC source: 0001104659-17-037006 · a4.xml · derivative · entry 1

Heier Jeffrey S. · CIK 0001653082 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,500

Underlying: Common Stock · 13,500 shares

Expires 2027-05-31

F1 · derivative.exercise_date: Vests with respect to 100% of the securities on the first anniversary of the grant date.